Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A Pilot Comparative study between I-DROP MGD vs two commercially available lubricant eye drops for the management of evaporative dry eye
Pilot, randomized, double-blind, prospective, non-inferiority study to demonstrate the safety and efficacy of I-DROP MGD vs two commercially available preservative-free lubricant eye drops for the management of evaporative dry eye
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| I-DROP MGD | Experimental | High Molecular weight hyaluronic acid + PC containing lubricant eye drop Receiving lubricant eye drops with high molecular weight hyaluronic acid |
|
| Thealoz Duo | Active Comparator | Low Molecular weight hyaluronic acid + Trehalose containing lubricant eye dropReceiving lubricant eye drops with low molecular weight hyaluronic acid |
|
| Systane Complet PF | Active Comparator | No hyaluronic acid containing lubricant eye drop Receiving lubricant eye drops without hyaluronic acid |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| I-DROP MGD | Device | All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Fluorescein Tear Break-Up Time (FTBUT) in seconds | The primary outcome of the study is FBUT at 30 minutes post-installation | Day 1 - 30 minutes post installation |
| Measure | Description | Time Frame |
|---|---|---|
| Fluorescein Tear Break-Up Time (FTBUT) in seconds | One of the secondary endpoints is FTBUT at day 7 and day 28 | Day 7 - day 28 |
| Tear Meniscus Height (TMH) in milimiters | One of the secondary endpoints is TMH at day 1 (30 minutes post-installation), 7 and day 28 |
Not provided
Inclusion Criteria:
Is at least 18 years of age and has full legal capacity to volunteer.
Has read and signed an information consent form.
Is willing and able to follow instructions and maintain the appointment schedule.
Has dry eye disease as per the TFOS DEWS II definition with a clear moderate to severe evaporative Dry Eye:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Karim Fahmy, Ph.D. | Contact | 1-800-463-1008 | kfahmy@imedpharma.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
in vivo, human patient with confirmed Evaporative dry eye disease
Not provided
Not provided
All products will have their label removed and placed a white sticker showing the group (A or B or C). Products with be put in a white box with the letter indicated on it.
| Theloze Duo | Device | All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30 |
|
| Systane Complete PF | Device | All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30 |
|
| Day 1 - Day 7 - day 28 |
| Osmolarity in mOsm/L | One of the secondary endpoints is osmolarity at day 1 (30 minutes post-installation), 7 and day 28 | Day 1 - Day 7 - day 28 |
| Number of Corneal and Conjunctival spots | One of the secondary endpoints is Corneal and conjunctival spots at day 7 and day 28 | Day 7 - day 28 |
| Ocular Surface and Disease Index (OSDI) score | One of the secondary endpoints is OSDI score at day 7 and day 28 | Day 7 - day 28 |
| ID | Term |
|---|---|
| D015352 | Dry Eye Syndromes |
| D000080343 | Meibomian Gland Dysfunction |
| ID | Term |
|---|---|
| D007766 | Lacrimal Apparatus Diseases |
| D005128 | Eye Diseases |
| D005141 | Eyelid Diseases |
Not provided
Not provided